title: Preoperative serum MMP-9 immunoreactive protein is a prognostic indicator for relapse-free survival in breast carcinoma.
abstract: The immunoreactive protein for the matrix metalloproteinase-9 (MMP-9) was studied prospectively from the pre-treatment sera of breast carcinoma patients using an enzyme-linked immunoassay (ELISA). The study comprised 71 primary breast carcinoma patients treated in Oulu University Hospital, Finland, between 1988 and 1991. The median follow-up time was over 10 years. Low preoperative serum MMP-9 (<54.5 ng/ml) was found to correlate with a poor relapse-free survival (RFS) in primary breast carcinoma. After 10 years of follow-up only 43% of the patients with low serum MMP-9 were disease-free, whereas 76% of the patients with high serum MMP-9 lived free of the disease (log-rank P=0.008). Low serum MMP-9 also indicated poor RFS in node-negative (P=0.03), stage I-II (P=0.01), progesterone receptor negative (P=0.008) carcinoma as well as in patients <50 years (P=0.02) with primary breast carcinoma. There was no statistical difference in overall survival. In multivariate analysis, preoperative low serum MMP-9 increases the risk of relapse 3.0-fold during the first 10 years of follow-up in primary breast carcinoma.
authors.affiliation: Department of Obstetrics and Gynecology, University of Oulu and University Hospital of Oulu, Box 24, Oulu 90029 OYS, Finland. anne.talvensaari-mattila@oulu.fi
authors.forename: Anne
authors.initials: A
authors.lastname: Talvensaari-Mattila
authors.forename: Taina
authors.initials: T
authors.lastname: Turpeenniemi-Hujanen
mesh_terms: D000328:Adult; D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000097:blood*; D001943:Breast Neoplasms / Q000097:blood* / Q000473:pathology / Q000601:surgery; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D008207:Lymphatic Metastasis / Q000473:pathology; D020780:Matrix Metalloproteinase 9 / Q000097:blood*; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000097:blood*; D009367:Neoplasm Staging; D011300:Preoperative Care; D011379:Prognosis; D011446:Prospective Studies; D011980:Receptors, Progesterone / Q000378:metabolism; D012307:Risk Factors
chemical_list: D014408:Biomarkers, Tumor; D011980:Receptors, Progesterone; D020780:Matrix Metalloproteinase 9